What Researchers Did
Researchers conducted a review to synthesize the research progress on hyperbaric oxygen therapy (HBOT) for ischaemic craniomaxillofacial diseases.
What They Found
They found that hyperbaric oxygen therapy (HBOT) shows promise as an adjunctive treatment for ischaemic craniomaxillofacial diseases, promoting angiogenesis, anti-inflammatory effects, bone regeneration, and antibacterial properties. HBOT was shown to stimulate healing processes in conditions like medication-related osteonecrosis of the jaw and osteoradionecrosis, accelerating recovery and reducing complications.
What This Means for Canadian Patients
Canadian patients suffering from ischaemic craniomaxillofacial diseases, such as osteonecrosis of the jaw, may benefit from hyperbaric oxygen therapy as an adjunctive treatment. This therapy could potentially accelerate healing, reduce complications, and improve overall quality of life for those with challenging conditions related to insufficient blood supply in the craniomaxillofacial region.
Canadian Relevance
This review did not report any specific Canadian connection or data.
Study Limitations
As a review, this study synthesizes existing literature but does not present new primary research data or clinical trial results.